Product hub: Pharma compliance
Could ELGA’s PURELAB® Pharma Compliance reliable, intuitive and simple to use GMP ready system be the future for your ultrapure water needs?
List view / Grid view
Could ELGA’s PURELAB® Pharma Compliance reliable, intuitive and simple to use GMP ready system be the future for your ultrapure water needs?
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…
Edward Samuel, EVP Technical Operations at Achilles Therapeutics, explains why industrialised manufacturing and scale-up of autologous cellular immunotherapies will require fully closed systems and process automation.
How to select a CDMO partner for the development and commercial manufacture, packaging and launch of products containing highly potent APIs.
After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.
Download this in-depth focus to discover why closed systems and process automation are key for industrialised autologous cell therapy manufacturing and how CMC strategies for cell and gene therapies need to evolve.
Features in this issue discuss how bioprocessing must adapt to meet the needs of autologous cell therapies, the role of mass spectrometry in enhancing antibody consistency and the economic benefits of embracing continuous manufacturing. Also in this journal, articles exploring the development of precision medicine for chronic diseases, why acoustic…
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production sites.
Evonetix has been granted a European patent for its silicon chips that leverage semiconductor technology to thermally control DNA synthesis.
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
7 April 2022 | By Charles River
Watch experts discuss key aspects of microbial investigations, helping you to understand and implement the new PDA Technical Report 88, and sharing their experience of investigating various microbial events in the real world.
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.